Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Boaz Nachmias, MD PhD, Geremy Godefroy, MD, Chezi Ganzel, MD, Neta Goldschmidt, MD, Eyal Rozenbach, MD, Rachel Bar-Shalom, MD, Diana Libster, MD, Vladimir Vainstein, MD

Blood (2019) 134 (Supplement_1): 5358.

https://doi.org/10.1182/blood-2019-121473

Published: 2019

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2014) 124 (21): 4409.

https://doi.org/10.1182/blood.V124.21.4409.4409

Published: 2014

Journal Articles

Hodgkin Lymphoma In First Remission: Routine PET/CT Imaging Is Not Superior To Clinical Follow-Up For Patients Without Residual Mass: Results Of a Bi-National Study Including 368 Patients

Eldad J Dann, MD, Leanne Berkahn, MB ChB, FRACP, FRCPA, Tatiana Mashiach, MSc, Michael Frumer, Ariel Agur, Bridgett McDiarmid, MD, Rachel Bar-Shalom, MD, Ora B. Paltiel, MSc, FRCPC, Neta Goldschmidt, MD

Blood (2013) 122 (21): 2995.

https://doi.org/10.1182/blood.V122.21.2995.2995

Published: 2013

Journal Articles

Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma

Noa Lavi, MD, Gali Shapira, MD, Ariel Zilberlicht, MD, Noam Benyamini, MD, Dan Farbstein, MD, Eldad J Dann, MD, Rachel Bar-Shalom, MD, Irit Avivi, MD

Blood (2013) 122 (21): 4296.

https://doi.org/10.1182/blood.V122.21.4296.4296

Published: 2013

Journal Articles

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Eldad J Dann, MD, Zeev Blumenfeld, MD, Rachel Bar-Shalom, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Odelia Goor, MD, Diana Libster, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2011) 118 (21): 1564.

https://doi.org/10.1182/blood.V118.21.1564.1564

Published: 2011

Journal Articles

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Irit Avivi, MD, Ariel Zilberlicht, MD, Eldad J Dann, MD, Jacob M. Rowe, MD, Ronit Leiba, MSc., Tal Faibish, MSc, Rachel Bar-Shalom, MD

Blood (2011) 118 (21): 1576.

https://doi.org/10.1182/blood.V118.21.1576.1576

Published: 2011

Journal Articles

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Liana Abdach, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Jacob M. Rowe, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MSc, FRCPC

Blood (2010) 116 (21): 2809.

https://doi.org/10.1182/blood.V116.21.2809.2809

Published: 2010

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Eldad J. Dann, MD, Ada Tamir, PhD, Ron Epelbaum, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2008) 112 (11): 1452.

https://doi.org/10.1182/blood.V112.11.1452.1452

Published: 2008

Journal Articles

In Patients with Aggressive Non-Hodgkin Lymphoma Treated with CHOP Therapy the Rapidity of Early Response, as Determined by Residual FDG Uptake, Does Not Impact on the Overall Prognosis.

Eldad J. Dann, MD, Eyal Fuchs, Ada Tamir, PhD, Irit Avivi, MD, Diana Gaitini, MD, Ora Israel, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2007) 110 (11): 2328.

https://doi.org/10.1182/blood.V110.11.2328.2328

Published: 2007

Journal Articles

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Eldad J. Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Nissim Haim, MD, Irit Avivi, MD, Diana Gaitini, MD, Menachem Ben-Shachar, MD, Ora Israel, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2006) 108 (11): 4589.

https://doi.org/10.1182/blood.V108.11.4589.4589

Published: 2006

Journal Articles

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Eldad J. Dann, MD, Rachel Bar Shalom, MD, Nissim Haim, MD, Ada Tamir, Ph.D, Menachem Ben Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Mark Kirschbaum, MD, Odelia Goor, MD, Diana Libster, MD, Jacob M. Rowe, MD, Ron Apelbaum, MD

Blood (2005) 106 (11): 815.

https://doi.org/10.1182/blood.V106.11.815.815

Published: 2005

NARROW

Post-Treatment FDG-Avid Splenic Lesions in DLBCL: Clinical and Radiographic Characteristics for Risk Assessment

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Hodgkin Lymphoma In First Remission: Routine PET/CT Imaging Is Not Superior To Clinical Follow-Up For Patients Without Residual Mass: Results Of a Bi-National Study Including 368 Patients

Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

In Patients with Aggressive Non-Hodgkin Lymphoma Treated with CHOP Therapy the Rapidity of Early Response, as Determined by Residual FDG Uptake, Does Not Impact on the Overall Prognosis.

Early Interim Negative FDG-PET/CT Is a High Predictive Factor for Progression-Free Survival in Hodgkin Lymphoma.

Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only